ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 503,27
-2,66%
Dow Jones
38 589,16
-0,15%
DAX
18 002,02
-1,43%
Brent Oil
82,275
0,00%
Bitcoin
66 468,97
0,42%
Registration Strip Icon for discussion Inscrivez-vous pour interagir sur nos forums actifs pour discuter avec des investisseurs aux idées similaires.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Silo Pharma Inc (SILO)

  7. Silo Pharma Inc (SILO) Actualités

SILO

Silo Pharma (SILO)

Silo Pharma Inc
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:SILO
DateHeureSourceTitreSymboleSociété
13/06/202423h08Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:SILOSilo Pharma Inc
13/06/202419h19Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SILOSilo Pharma Inc
11/06/202422h00Edgar (US Regulatory)Form D - Notice of Exempt Offering of SecuritiesNASDAQ:SILOSilo Pharma Inc
07/06/202414h18GlobeNewswire Inc.Silo Pharma Announces Successful Production of its SP-26 Ketamine Implant for FibromyalgiaNASDAQ:SILOSilo Pharma Inc
06/06/202422h52Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SILOSilo Pharma Inc
06/06/202422h50GlobeNewswire Inc.Silo Pharma Announces Closing of $2 Million Registered Direct Offering Priced At-The-Market Under Nasdaq RulesNASDAQ:SILOSilo Pharma Inc
06/06/202412h07Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:SILOSilo Pharma Inc
05/06/202414h00GlobeNewswire Inc.Silo Pharma Announces $2 Million Registered Direct Offering Priced At-The-Market Under Nasdaq RulesNASDAQ:SILOSilo Pharma Inc
04/06/202414h41GlobeNewswire Inc.Silo Pharma Submits Pre-Investigational New Drug Application to FDA for SPC-15 as a Treatment for PTSD and AnxietyNASDAQ:SILOSilo Pharma Inc
21/05/202414h45GlobeNewswire Inc.Silo Pharma Announces Positive Results from Study for Depression Treatment, Remission, and Relapse PreventionNASDAQ:SILOSilo Pharma Inc
14/05/202414h45GlobeNewswire Inc.Silo Pharma to Participate in FDA Meeting Exploring Emerging Therapeutic Interest in KetamineNASDAQ:SILOSilo Pharma Inc
13/05/202422h05Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:SILOSilo Pharma Inc
23/04/202414h15GlobeNewswire Inc.Silo Pharma Announces Positive Results for Intranasal PTSD TreatmentNASDAQ:SILOSilo Pharma Inc
10/04/202414h11GlobeNewswire Inc.Silo Pharma set to Acquire Exclusive Licensing for Promising Alzheimer’s Disease TherapeuticNASDAQ:SILOSilo Pharma Inc
20/03/202413h30GlobeNewswire Inc.Silo Pharma Exercises Option for Exclusive License Agreement for First-in-Class PTSD and Stress-Induced Anxiety TherapeuticNASDAQ:SILOSilo Pharma Inc
18/03/202412h15GlobeNewswire Inc.Silo Pharma Files Patent for Groundbreaking Ketamine Implant Therapeutic to Target Fibromyalgia and Chronic PainNASDAQ:SILOSilo Pharma Inc
28/02/202414h25GlobeNewswire Inc.Silo Pharma Completes Successful Dose-Ranging Study of SPC-15 Intranasal Therapeutic for PTSDNASDAQ:SILOSilo Pharma Inc
14/02/202414h45GlobeNewswire Inc.Silo Pharma’s SP-26 Ketamine Implant Demonstrates Successful Drug DeliveryNASDAQ:SILOSilo Pharma Inc
01/02/202416h00GlobeNewswire Inc.Silo Pharma Announces Pipeline Prioritization for 2024 Targeting Mental Health, Chronic Pain, and NeurologyNASDAQ:SILOSilo Pharma Inc
31/01/202406h15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:SILOSilo Pharma Inc
25/01/202423h29Edgar (US Regulatory)Form S-3/A - Registration statement under Securities Act of 1933: [Amend]NASDAQ:SILOSilo Pharma Inc
25/01/202423h27Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:SILOSilo Pharma Inc
24/01/202414h55GlobeNewswire Inc.Silo Pharma Announces Positive Results in Alzheimer’s Disease StudyNASDAQ:SILOSilo Pharma Inc
23/01/202423h01Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:SILOSilo Pharma Inc
11/01/202418h15Edgar (US Regulatory)Form 8-K/A - Current report: [Amend]NASDAQ:SILOSilo Pharma Inc
04/01/202414h55GlobeNewswire Inc.Silo Pharma Successfully Completes First Phase of Dose-Ranging Study of SPC-15 an Intranasal Treatment for PTSDNASDAQ:SILOSilo Pharma Inc
28/12/202314h25GlobeNewswire Inc.Silo Pharma and Partner Receive Regulatory Approval to Begin Development of Ketamine Implant for FibromyalgiaNASDAQ:SILOSilo Pharma Inc
20/12/202322h58Edgar (US Regulatory)Form 8-K12B - Notification that a class of securities of successor issuer is deemed to be registered pursuant to section 12(b)NASDAQ:SILOSilo Pharma Inc
21/11/202314h01GlobeNewswire Inc.Silo Pharma Enters into Exclusive License Agreement with Medspray Pharma BV for Intranasal Technology used in SPC-15 Treatment for PTSDNASDAQ:SILOSilo Pharma Inc
08/11/202314h11GlobeNewswire Inc.Silo Pharma to Initiate Dose-Ranging Study of Novel Intranasal Therapeutic SPC-15 for the Treatment of PTSDNASDAQ:SILOSilo Pharma Inc
 Showing the most relevant articles for your search:NASDAQ:SILO

Dernières Valeurs Consultées

EU
ORA
Orange
NYSE
MCD
McDonalds
FTSE
UKX
FTSE 100
NASDAQ
GOOGL
Alphabet
COIN
BTCUSD
Bitcoin
EU
DG
Vinci
EU
HO
Thales
EU
VIV
Vivendi
NYSE
NKE
Nike
SPI
SP500
S&P 500
EU
BEL20
Bel 20
EU
LR
Legrand
EU
PX4
SBF 120
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés